Antibody Internalization
Accelerate Your Antibody-Drug Conjugate (ADC) Discovery with Nanobody Technology
Revolutionary tools designed to simplify, accelerate, and reduce the cost of antibody internalization assays and ADC pre-screening
Antibody-drug conjugates (ADCs) represent a leading class of targeted cancer therapies. The efficacy of an ADC relies heavily on the internalization of the antibody to release the cytotoxic payload specifically within tumor cells. Traditional screening for internalization candidates is often slow, expensive, and technically challenging.
Echo Bio offers a revolutionary suite of Nanobody-based tools designed to simplify, accelerate, and reduce the cost of antibody internalization assays and ADC pre-screening.
ADC-VHH Cytotoxicity screener
Rapid, Cost-Effective Pre-Screening for Cytotoxicity
The ADC Cytotoxicity Screener is a secondary antibody-drug conjugate that uses a high-affinity nanobody (VHH) linked to potent toxins (MMAE, MMAF, DXD, or PBD). It binds specifically to the Fc or Kappa region of your primary monoclonal antibody, instantly converting it into a pseudo-ADC for cell-based killing assays
Key Advantages:
📊 Research Case Study
The data below demonstrate the cytotoxic profile of Herceptin (Trastuzumab) on SKBR3 cells. Herceptin alone does not kill the cells in this assay. However, when combined with the Anti-Human IgG Nano-Secondary ADC (VcMMAE), it demonstrates potent cell killing capabilities.
| Product Name | Conjugate | Application |
|---|---|---|
| ADC-Screener™ Anti-Human IgG Fc, VHH(VcMMAE×4)) | VcMMAE | Antibody-drug conjugate screening |
| ADC-Screener™ Anti-Human IgG Fc, VHH(VcMMAE×8) | VcMMAE | Antibody-drug conjugate screening |
| ADC-Screener™ Anti-Human IgG Fc, VHH(GGFG-DXDx4) | GGFG-DXD | Antibody-drug conjugate screening |
| ADC-Screener™ Anti-Human IgG Fc, VHH(GGFG-DXDx8) | GGFG-DXD | Antibody-drug conjugate screening |
Nano-DT (Next-Gen Internalization Detection)
Superior Sensitivity Over DT-3C
Traditional DT-3C reagents use Protein G to bind antibodies, which often results in non-specific binding to bovine IgG in serum, causing high background noise. VHH-DT replaces Protein G with a high-affinity Nanobody that does not bind bovine IgG, offering a cleaner, more sensitive signal
Key Advantages:
📊 Research Case Study
| Product Name | Conjugate | Application |
|---|---|---|
| Endo-Toxic™ Anti-Mouse IgG, VHH (DT) | Diphtheria Toxin (DT | Antibody-drug conjugate screening |
| Endo-Toxic™ Anti-Human IgG, VHH (DT) | Diphtheria Toxin (DT | Antibody-drug conjugate screening |
Dual Payload ADC System
Precision Assembly for Dual-Toxin Delivery
Leveraging the specificity of nanobodies, we enable the construction of Dual-Toxin Payload ADCs. By targeting different constant regions of the same human IgG (e.g., the Fc region and the Kappa light chain), two different toxins can be delivered simultaneously.
Toxins available: MMAE, MMAF, DXD, and PBD; Or customers provided
VHH-pH-Sensitive Probes
Wash-Free Endocytosis Detection
These probes consist of nanobodies coupled to pH-dependent fluorescent dyes. These dyes are non-fluorescent at neutral pH (outside the cell) but fluoresce brightly upon internalization into the acidic environment of endosomes and lysosomes. Applicable to a variety of detection systems: fluorescence imaging systems, high-content analysis, flow cytometry.
| Product Name | Conjugate | Application |
|---|---|---|
| Endo-Sight™ Anti-Mouse IgG, VHH( pH-Red630) | pH-Red630 | Imaging, flow cytometry, high-content analysis |
| Endo-Sight™ Anti-Human IgG, VHH( pH-Red630) | pH-Red630 | Imaging, flow cytometry, high-content analysis |
Your Partner in VHH-Based Therapy Development Specializing in high-performance alpaca nanobodies and recombinant reagents.
Your Partner in VHH-Based Therapy Development
Specializing in high-performance alpaca nanobodies and recombinant reagents